New York Blood Center
Executive Summary
The center announced that it has received a patent for chemical process which inactivates hepatitis and HTLV-III viruses in blood protein derivatives "without affecting the functioning of the proteins in the coagulation factor concentrates or the activity of other blood proteins." The process destroys the viruses by disrupting the lipid containing envelope surrounding hepatitis and HTLV-II viruses which is necessary for the viruses to bind to and infect cells.